Francisco Ujueta/LinkedIn;
Eric A Secemsky/LinkedIn
Apr 12, 2026, 13:44
Francisco Ujueta: PAD VS CAD – Why Individualized Antithrombotic Strategies Matter
Francisco Ujueta, Vascular Cardiologist at Vanderbilt University Medical Center, shared a post on LinkedIn about a recent article he and his colleague co-authored, adding:
“View our commentary on differences in PAD and CAD – emphasizing higher ischemic and bleeding risks, greater heterogeneity, and the need for individualized antithrombotic strategies.”
Title: Too much, too little, or just right: Tailoring postrevascularization antithrombotic therapy in PAD versus CAD when one size does not fit all
Authors: Francisco Ujueta, Eric A Secemsky
Read the Full Article on Vascular Medicine
Stay updated with Hemostasis Today.
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care
-
May 27, 2026, 15:59Piotr Czempik: First Report of ROTEM Findings in Triple-Positive APS and Hageman Anomaly
-
May 27, 2026, 15:59Sara Trompeter: Improving Transfusion Safety Through Advanced Blood Matching in SCD
-
May 27, 2026, 15:58Hassan Raza: Global Advocacy for People With Bleeding Disorders Must Continue Beyond Adoption
-
May 27, 2026, 15:43Aryabhatta Sadhu: Effective Hemotherapy Beyond Transfusion
-
May 27, 2026, 15:38Wolfgang Miesbach: How Haemophilia Care Has Evolved in China
-
May 27, 2026, 15:27Saja Abo Thyab: How MDS Can Progress to AML